Evidence map›Paper›PMID 38353897›Full record

ArticleActa neurologica Belgica2024

Favorite colors of patients with drug-resistant epilepsy: pilot study.

Suljo Kunić, Omer Ć Ibrahimagić, Dževdet Smajlović, Amela Kunić, Jasmin Alić, Muhamed Lepuzanović, Merita Tirić-Čampara, Aida Šehanović

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neurologica Belgica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Suljo KunićDepartment of Neurology, Primary Health Care Center Tuzla, 75000, Tuzla, Bosnia and Herzegovina. suljo.kunic@hotmail.com.ORCID http://orcid.org/0000-0001-7900-1222
Omer Ć IbrahimagićMedical Faculty, University of Tuzla, 75000, Tuzla, Bosnia and Herzegovina.
Dževdet SmajlovićMedical Faculty, University of Tuzla, 75000, Tuzla, Bosnia and Herzegovina.
Amela KunićMedical Faculty, University of Tuzla, 75000, Tuzla, Bosnia and Herzegovina.
Jasmin AlićEmergency Medical Service, Primary Health Care Center Lukavac, 75300, Lukavac, Bosnia and Herzegovina.
Muhamed LepuzanovićDepartment of Neuropsychiatry, Cantonal Hospital Bihać, 77000, Bihać, Bosnia and Herzegovina.
Merita Tirić-ČamparaDepartment of Neurology, General Hospital Sarajevo, 71000, Sarajevo, Bosnia and Herzegovina.
Aida ŠehanovićMedical Faculty, University of Tuzla, 75000, Tuzla, Bosnia and Herzegovina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the favorite colors of patients with drug-resistant epilepsy.

methodsFollowing examination, 50 patients were diagnosed in accordance with the 2005 proposal of the International League Against Epilepsy and the definition of drugresistant epilepsy since 2010. The favorite color examination used a six-color tape and Trycolors, an online color mixing tool. The patients' color preferences were compared with those of 50 individuals without epilepsy.

resultsPatients with drug-resistant epilepsy preferred the color blue the most (30%), significantly more yellow (p = 0.0001), and significantly less green (p < 0.0001) compared to individuals without epilepsy. By mixing these colors at a certain percentage, we obtained the Go Ben color. SIGNIFICANCE: This information on preferred colors can help to improve compliance and can be utilized in designing medications and environments for patients with epilepsy.

Indexed as

ColorDrug Resistant EpilepsyAdolescentAdultFemaleHumansMaleMiddle AgedPatient PreferencePilot ProjectsYoung AdultColorComplianceDrugEpilepsy

Identifiers

PMID38353897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.